Pharmacology and the Cardiac Patient with Obesity, Diabetes or Atrial Fibrillation
Clinical management of chronic cardiovascular disease is a key component of the work of advanced practice nurses and RNs in the cardiology and primary care settings. PCNA develops an annual pharmacology CE program to meet the clinical practice and recertification needs of these clinicians.
This 2018 course curriculum includes a comprehensive approach to pharmacology in:
- Medications Management of Excess Weight and Co-Morbid Conditions
- Anti-Hyperglycemic Therapies: Improving CVD Outcomes
- Medications to Manage Rate, Rhythm and Symptoms Associated with Atrial Fibrillation and Flutter.
This is an independent self-paced course with pre- and post-course evaluations.
Upon completion of this continuing education course, participants will be able to:
- Review National Guidelines for the Management of Obesity and the recommendations regarding pharmacotherapy in relationship to behavioral interventions and surgical procedures.
- List FDA-approved medications for weight management and their approved dosing, schedule, adverse effects and contraindications.
- Describe, using case examples, how to match patients with co-morbid conditions to safe and effective weight management therapies.
- Describe the new challenge for cardiology in prescribing medications to manage diabetes, as well as CVD.
- Review recent clinical trials of anti-hyperglycemic therapies, cardiovascular outcomes, and impact on FDA indications.
- Discuss appropriate anti hyperglycemic therapy selection, dose, and potential side effects in selected case studies.
- List common medications used to control heart rate in patients with atrial fibrillation and flutter along with appropriate dose, schedule, adverse effects, and contraindications.
- Describe the role of medications in cardio version and maintenance of sinus rhythm in patients with atrial fibrillation and flutter, along with appropriate dose, schedule, adverse effects, and contraindications.
- Review common symptoms associated with atrial fibrillation and flutter and discuss the impact of heart rate and rhythm control therapies on these symptoms.
- Course Director: Cindy Lamendola, MSN, NP, FAHA, FPCNA
- Melissa Davis, DNP, ANP-BC, CNS, CBN, CNOR, RNFA
- T. Jennifer Walker, ANP-BC